Urovant reports positive data from Phase IIa OAB therapy trial
In the trial, single doses of URO-902 demonstrated to be well tolerated versus placebo.

In the trial, single doses of URO-902 demonstrated to be well tolerated versus placebo.
GlobalData expects there will still be a considerable level of unmet need remaining in the overactive bladder segment by 2030.
ByMacroGenics in multiple cancers and Merck’s Bavencio are among other assets reviewed by GlobalData’s Investigative News team.
ByNatural health firm Semaine discusses its new approach to period pain and what it’s like to run trials as a…
ByNew research into urinary incontinence could aid the development of targeted treatment methods for overactive bladder and other similar conditions.
ByNIH kick starts hunt for neuroprotective stroke treatments and Denali begins dosing Parkinson’s patients in Phase Ib trial. Clinicaltrialsarena.com wraps…